Avalo Therapeutics reported its 2025 financial results, showing a net loss of $78.3 million compared with a $35.1 million loss in 2024. Revenue for the year was $59,000, reflecting the company’s pre‑revenue status.
Research and development expenses increased by $25.6 million, largely driven by costs associated with the Phase 2 LOTUS trial of AVTX‑009. General and administrative expenses rose by $5.7 million, mainly due to stock‑based compensation and headcount additions. The widening loss was also influenced by a change in other income and expenses related to warrants.
CEO Dr. Garry Neil said the company has maintained disciplined execution while advancing the LOTUS trial, and that the upcoming topline data in the second quarter of 2026 could be transformational.
The results underscore the company’s focus on the AVTX‑009 program, with cash reserves and runway remaining a priority as the Phase 2 trial progresses. A positive Q2 2026 data release could de‑risk the asset and open the path to Phase 3 development.
Avalo’s pipeline also includes quisovalimab and AVTX‑008, but the primary commercial opportunity remains the treatment of hidradenitis suppurativa, a condition with significant unmet need and competition from other IL‑1 inhibitors.
Overall, the financials reflect the expected investment pattern of a clinical‑stage biotech, with losses expanding as R&D spending increases, while the company remains focused on delivering clinical data that will shape its future trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.